Fosamprenavir

Fosamprenavir (marketed by GlaxoSmithKline as fosamprenavir calcium, under the trade name Lexiva®) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir.

© Medic8 ® All Rights Reserved.